Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?

Hepato-Gastroenterology

Volumn 57, Issue 98, 2010, Pages 388-394

  Drescher, Daniel ^a   Gockel, Ines ^a   Timm, Stephan ^a   Berger, Martin R ^b   Herzer, Kerstin ^a   Schmidtmann, Irene ^c   Junginger, Theodor ^a   Galle, Peter R ^a   Lang, Hauke ^a   Moehler, Markus ^a   Schimanski, Carl C ^a,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d IZKS Mainz   (Germany)

Author keywords

Adenocarcinoma; Gastric; Receptor tyrosine kinases; Stomach

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR SUBTYPE; RNA; TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 77954090291     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001; 94(2):153-156.
2. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8:S4-66.
3. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996; 46(1):5-27.
4. Vaughan TL, Davis S, Kristal A, Thomas DB: Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4(2):85-92.
5. Moehler M, Schimanski CC, Gockel I, Junginger T, Galle PR: (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 2004; 22(4):345-350.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1):11-20.
7. Zagari RM, Bazzoli F: Gastric cancer: who is at risk? Dig Dis 2004; 22(4):302-305.
8. Mattar R, Nonogaki S, Silva C, Alves V, Gama-Rodrigues JJ: P53 and Rb tumor suppressor gene alterations in gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2004; 59(4):172-180.
9. Tamura G: Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12(2):192-198.
10. Wang D, Fang D, Luo Y, Lu R, Liu W: Study of loss of heterozygosity at DCC and APC/MCC genetic loci of gastric cancer. Chin Med Sci J 1999; 14(2):107-111.
11. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Shimamoto F, Chayama K: K-ras mutation in helicobacter pyloriassociated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002; 97(5):562-566. (Pubitemid 34087791)
12. Li E, Hristova K: Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006; 45(20):6241-6251.
13. Argraves WS, Drake CJ: Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice. Anat Rec A Discov Mol Cell Evol Biol 2005; 286(2):875-884.
14. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005; 104(11):2323-2333.
15. Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P, Cavo M, Guidolin D, Ribatti D, Dammacco F: A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004; 92(6):1438-1445.
16. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ: Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18(4):485-494.
17. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR: The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003; 29(10):890-894.
18. Liu XE, Sun XD, Wu JM: Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004; 10(3):352-355. (Pubitemid 38208085)
19. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, Sasaki T, Miura M: Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol 2005; 10(5):318-327.
20. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2(10):1679-1684. (Pubitemid 26356351)
21. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75(6 Suppl):1418-1425.
22. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A et al: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007; 109(4):658-667.
23. Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T et al: Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol 2007; 13(26):3605-3609.
24. An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M et al: Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 2004; 111(2):165-173.
25. del Casar JM, Corte MD, Alvarez A, Garcia I, Bongera M, Gonzalez LO, Garcia-Muniz JL, Allende MT, Astudillo A, Vizoso FJ: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol 2008; 134(2):153-161.
26. Ozdemir F, Akdogan R, Aydin F, Reis A, Kavgaci H, Gul S, Akdogan E: The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res 2006; 25(1):83-88.
27. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24(2):228-240.
28. Han FH, Zhan WH, He YL, Li YM, Zheng ZQ, Peng JS, Cai SR, Ma JP: The expression of VEGF-C, VEGFR-3 and its predictive value on lymph node metastasis and prognosis of gastric cancer. Zhonghua Wai Ke Za Zhi 2006; 44(15):1058-1061
29. Sung JY, Lee S, Kim YW, Park YK: Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma. Oncol Rep 2008; 19(4):939-944. (Pubitemid 351802663)
30. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstadter C, Nahrig J, Becker KF et al: Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004; 17(5):579-587.
31. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, Pfeiffer DG, Schildberg FW, Pfeiffer A: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003; 162:115-132.
32. Tsuda T, Yoshida K, Tsujino T, Nakayama H, Kajiyama G, Tahara E: Coexpression of platelet-derived growth factor (PDGF) A-chain and PDGF receptor genes in human gastric carcinomas. Jpn J Cancer Res 1989; 80(9):813-817. (Pubitemid 20030345)
33. Chung CK, Antoniades HN: Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res 1992; 52(12):3453-3459.
34. Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, Biesterfeld S, Berger MR, Kanzler S, Junginger T, Galle PR et al: PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep 2008; 19(3):697-704.